Cytochrome P450 1B1 promotes cancer cell survival via specificity protein 1 (Sp1)-mediated suppression of death receptor 4

References

• Ashkenazi, A. 2002. Targeting death and decoy receptors of the tumour-necrosis factor superfamily. Nature Reviews Cancer 2:420–30. doi:10.1038/nrc821.
   PubMed Web of Science ®Google Scholar
• Baylin, S. B., and P. A. Jones. 2011. A decade of exploring the cancer epigenome – biological and translational implications. Nature Reviews Cancer 11:726–34. doi:10.1038/nrc3130.
   PubMed Web of Science ®Google Scholar
• Chang, I., Y. Mitsui, S. K. Kim, J. S. Sun, H. S. Jeon, J. Y. Kang, N. J. Kang, S. Fukuhara, A. Gill, V. Shahryari, Z. L. Tabatabai, K. L. Greene, R. Dahiya, D. M. Shin, and Y. Tanaka. 2017. Cytochrome P450 1B1 inhibition suppresses tumorigenicity of prostate cancer via caspase-1 activation. Oncotarget 8:39087–100.
   PubMedGoogle Scholar
• Chin, L., J. N. Andersen, and P. A. Futreal. 2011. Cancer genomics: From discovery science to personalized medicine. Nature Medicine 17:297–303. doi:10.1038/nm.2323.
   PubMed Web of Science ®Google Scholar
• Chu, S., and T. J. Ferro. 2005. Sp1: Regulation of gene expression by phosphorylation. Gene 348:1–11. doi:10.1016/j.gene.2005.01.013.
   PubMed Web of Science ®Google Scholar
• Chun, Y. J., S. Kim, D. Kim, S. K. Lee, and F. P. Guengerich. 2001. A new selective and potent inhibitor of human cytochrome P450 1B1 and its application to antimutagenesis. Cancer Research 61:8164–70.
   PubMed Web of Science ®Google Scholar
• Chun, Y. J., Y. K. Oh, B. J. Kim, D. Kim, S. S. Kim, H. K. Choi, and M. Y. Kim. 2009. Potent inhibition of human cytochrome P450 1B1 by tetramethoxystilbene. Toxicology Letters 189:84–89. doi:10.1016/j.toxlet.2009.05.005.
   PubMed Web of Science ®Google Scholar
• Clark, P. M., V. A. Ebiana, L. Gosa, T. F. Cloughesy, and D. A. Nathanson. 2017. Harnessing preclinical molecular imaging to inform advances in personalized cancer medicine. Journal of Nuclear Medicine 58:689–96. doi:10.2967/jnumed.116.181693.
   PubMed Web of Science ®Google Scholar
• D’Uva, G., D. Baci, A. Albini, and D. M. Noonan. 2018. Cancer chemoprevention revisited: Cytochrome P450 family 1B1 as a target in the tumor and the microenvironment-cancer treatment reviews. Cancer Treatment Reviews 63:1–18. doi:10.1016/j.ctrv.2017.10.013.
   PubMed Web of Science ®Google Scholar
• Dawson, M. A., and T. Kouzarides. 2012. Cancer epigenetics: From mechanism to therapy. Cell 150:12–27. doi:10.1016/j.cell.2012.06.013.
   PubMed Web of Science ®Google Scholar
• Fagundes, G. E., A. P. Damiani, G. D. Borges, K. O. Teixeira, M. M. Jesus, F. Daumann, F. Ramlov, T. Carvalho, D. D. Leffa, P. Rohr, and V. Moraes De Andrade. 2017. Effect of green juice and their bioactive compounds on genotoxicity induced by alkylating agents in mice. Journal of Toxicology and Environmental Health, Part A 80:756–66. doi:10.1080/15287394.2017.1357307.
   PubMed Web of Science ®Google Scholar
• Goll, M. G., and T. H. Bestor. 2005. Eukaryotic cytosine methyltransferases. Annual Review of Biochemistry 74:481–514. doi:10.1146/annurev.biochem.74.010904.153721.
   PubMed Web of Science ®Google Scholar
• Hopkins-Donaldson, S., A. Ziegler, S. Kurtz, C. Bigosch, D. Kandioler, C. Ludwig, U. Zangemeister-Wittke, and R. Stahel. 2003. Silencing of death receptor and caspase-8 expression in small cell lung carcinoma cell lines and tumors by DNA methylation. Cell Death and Differentiation 10:356–64. doi:10.1038/sj.cdd.4401157.
   PubMed Web of Science ®Google Scholar
• Horak, P., D. Pils, G. Haller, I. Pribill, M. Roessler, S. Tomek, R. Horvat, R. Zeillinger, C. Zielinski, and M. Krainer. 2005. Contribution of epigenetic silencing of tumor necrosis factor-related apoptosis inducing ligand receptor 1 (DR4) to TRAIL resistance and ovarian cancer. Molecular Cancer Research 3:335–43. doi:10.1158/1541-7786.MCR-04-0136.
   PubMed Web of Science ®Google Scholar
• Huang, H., Y. Ji, J. Zhang, Z. Su, M. Liu, J. Tong, C. Ge, T. Chen, and J. Li. 2017. Aberrant DNA methylation in radon and/or cigarette smoke-induced malignant transformation in BEAS-2B human lung cell line. Journal of Toxicology and Environmental Health, Part A 80:1321–30. doi:10.1080/15287394.2017.1384156.
   PubMed Web of Science ®Google Scholar
• Johnstone, R. W., A. J. Frew, and M. J. Smyth. 2008. The TRAIL apoptotic pathway in cancer onset, progression and therapy. Nature Reviews Cancer 8:782–98. doi:10.1038/nrc2465.
   PubMed Web of Science ®Google Scholar
• Kang, K. A., and J. W. Hyun. 2017. Oxidative stress, Nrf2, and epigenetic modification contribute to anticancer drug resistance. Toxicological Researcher 33:1–5. doi:10.5487/TR.2017.33.1.001.
   PubMed Web of Science ®Google Scholar
• Kelley, S. K., and A. Ashkenazi. 2004. Targeting death receptors in cancer with Apo2L/TRAIL. Current Opinion in Pharmacology 4:333–39. doi:10.1016/j.coph.2004.02.006.
   PubMed Web of Science ®Google Scholar
• Kim, J. E., and Y. J. Park. 2017. Improved antitumor efficacy of hyaluronic acid-complexed Paclitaxel nanoemulsions in treating non-small cell lung cancer. Biomolecules & Therapeutics 25:411–16. doi:10.4062/biomolther.2016.261.
   PubMed Web of Science ®Google Scholar
• Kluetz, P. G., A. Slagle, E. J. Papadopoulos, L. L. Johnson, M. Donoghue, V. E. Kwitkowski, W. H. Chen, R. Sridhara, A. T. Farrell, P. Keegan, G. Kim, and R. Pazdur. 2016. Focusing on core patient-reported outcomes in cancer clinical trials: Symptomatic adverse events, physical function, and disease-related symptoms. Clinical Cancer Research 22:1553–58. doi:10.1158/1078-0432.CCR-15-2035.
   PubMed Web of Science ®Google Scholar
• Kwon, Y. J., H. S. Baek, D. J. Ye, S. Shin, D. Kim, and Y. J. Chun. 2016. CYP1B1 enhances cell proliferation and metastasis through induction of EMT and activation of Wnt/β-catenin signaling via Sp1 upregulation. PLoS One 11:e0151598. doi:10.1371/journal.pone.0151598.
   PubMed Web of Science ®Google Scholar
• LeBlanc, H. N., and A. Ashkenazi. 2003. Apo2L/TRAIL and its death and decoy receptors. Cell Death and Differentiation 10:66–75. doi:10.1038/sj.cdd.4401187.
   PubMed Web of Science ®Google Scholar
• Lin, R. K., C. Y. Wu, J. W. Chang, L. J. Juan, H. S. Hsu, C. Y. Chen, Y. Y. Lu, Y. A. Tang, Y. C. Yang, P. C. Yang, and Y. C. Wang. 2010. Dysregulation of p53/Sp1 control leads to DNA methyltransferase-1 overexpression in lung cancer. Cancer Research 70:5807–17. doi:10.1158/0008-5472.CAN-09-4161.
   PubMed Web of Science ®Google Scholar
• Lopes-Costa, E., M. Abreu, D. Garqiulo, E. Rocha, and A. A. Ramos. 2017. Anticancer effects of seaweed compounds fucoxanthin and phloroglucinol, alone and in combination with 5-fluorouracil in colon cells. Journal of Toxicology and Environmental Health, Part A 80:776–87. doi:10.1080/15287394.2017.1357297.
   PubMed Web of Science ®Google Scholar
• Micheau, O., S. Shirley, and F. Dufour. 2013. Death receptors as targets in cancer. British Journal of Pharmacology 169:1723–44. doi:10.1111/bph.12238.
   PubMed Web of Science ®Google Scholar
• Murray, G. I., M. C. Taylor, M. C. McFadyen, J. A. McKay, W. F. Greenlee, M. D. Burke, and W. T. Melvin. 1997. Tumor-specific expression of cytochrome P450 CYP1B1. Cancer Research 57:3026–31.
   PubMed Web of Science ®Google Scholar
• Nagarsheth, N., M. S. Wicha, and W. P. Zou. 2017. Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy. Nature Reviews Immunology 17:559–72. doi:10.1038/nri.2017.49.
   PubMed Web of Science ®Google Scholar
• Nebbioso, A., R. Pereira, H. Khanwalkar, F. Matarese, J. Garcia-Rodriguez, M. Miceli, C. Logie, V. Kedinger, F. Ferrara, H. G. Stunnenberg, A. R. de Lera, H. Gronemeyer, and L. Altucci. 2011. Death receptor pathway activation and increase of ROS production by the triple epigenetic inhibitor UVI5008. Molecular Cancer Therapeutics 10:2394–404. doi:10.1158/1535-7163.MCT-11-0525.
   PubMed Web of Science ®Google Scholar
• Ozoren, N., and W. S. El-Deiry. 2003. Cell surface death receptor signaling in normal and cancer cells. Seminars in Cancer Biology 13:135–47. doi:10.1016/S1044-579X(02)00131-1.
   PubMed Web of Science ®Google Scholar
• Saini, S., H. Hirata, S. Majid, and R. Dahiya. 2009. Functional significance of cytochrome P450 1B1 in endometrial carcinogenesis. Cancer Research 69:7038–45. doi:10.1158/0008-5472.CAN-09-1691.
   PubMed Web of Science ®Google Scholar
• Schaefer, U., O. Voloshanenko, D. Willen, and H. Walczak. 2007. TRAIL: A multifunctional cytokine. Frontiers in Bioscience 12:3813–24. doi:10.2741/2354.
   PubMed Web of Science ®Google Scholar
• Shivapurkar, N., S. Toyooka, K. O. Toyooka, J. Reddy, K. Miyajima, M. Suzuki, H. Shigematsu, T. Takahashi, G. Parikh, H. I. Pass, P. M. Chaudhary, and A. F. Gazdar. 2004. Aberrant methylation of trail decoy receptor genes is frequent in multiple tumor types. International Journal of Cancer 109:786–92. doi:10.1002/(ISSN)1097-0215.
   PubMed Web of Science ®Google Scholar
• Siegel, R. L., K. D. Miller, and A. Jemal. 2017. Cancer statistics, 2017. CA: A Cancer Journal for Clinicians 67:7–30. doi:10.3322/caac.21387.
   PubMed Web of Science ®Google Scholar
• Smyth, M. J., E. Cretney, J. M. Kelly, J. A. Westwood, S. E. Street, H. Yagita, K. Takeda, S. L. van Dommelen, M. A. Degli-Esposti, and Y. Hayakawa. 2005. Activation of NK cell cytotoxicity. Molecular Immunology 42:501–10. doi:10.1016/j.molimm.2004.07.034.
   PubMed Web of Science ®Google Scholar
• Valdiglesias, V., M. Sánchez-Flores, A. Maseda, L. Lorenzo-López, D. Marcos-Pérez, A. López-Cortón, B. Strasser, D. Fuchs, B. Laffon, J. C. Millán-Calenti, and E. Pásaro. 2017. Immune biomarkers in older adults: Role of physical activity. Journal of Toxicology and Environmental Health, Part A 80:605–20. doi:10.1080/15287394.2017.1286898.
   PubMed Web of Science ®Google Scholar
• Vanneman, M., and G. Dranoff. 2012. Combining immunotherapy and targeted therapies in cancer treatment. Nature Reviews Cancer 12:237–51. doi:10.1038/nrc3237.
   PubMed Web of Science ®Google Scholar
• von Roemeling, C., W. Jiang, C. K. Chan, I. L. Weissman, and B. Y. Kim. 2017. Breaking down the barriers to precision cancer nanomedicine. Trends in Biotechnology 35:159–71. doi:10.1016/j.tibtech.2016.07.006.
   PubMed Web of Science ®Google Scholar
• Walczak, H., R. E. Miller, K. Ariail, B. Gliniak, T. S. Griffith, M. Kubin, W. Chin, J. Jones, A. Woodward, T. Le, C. Smith, P. Smolak, R. G. Goodwin, C. T. Rauch, J. C. Schuh, and D. H. Lynch. 1999. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nature Medicine 5:157–63. doi:10.1038/5517.
   PubMed Web of Science ®Google Scholar
• Wilhelm, S., A. J. Tavares, Q. Dai, S. Ohta, J. Audet, H. F. Dvorak, and W. C. W. Chan. 2016. Analysis of nanoparticle delivery to tumours. Natural Reviews Materials 1:16014. doi:10.1038/natrevmats.2016.14.
   Web of Science ®Google Scholar
• Wong, J. K. L., R. Mohseni, A. A. Hamidieh, R. E. MacLaren, N. Habib, and A. M. Seifalian. 2017. Limitations in clinical translation of nanoparticle-based gene therapy. Trends in Biotechnology 35:1124–25. doi:10.1016/j.tibtech.2017.07.009.
   PubMed Web of Science ®Google Scholar
• Yang, J., X. Tian, J. Yang, J. Cui, S. Jiang, R. Shi, Y. Liu, X. Liu, W. Xu, W. Xie, X. Jia, R. Bade, T. Zhang, M. Zhang, K. Gong, S. Yan, Z. Yang, and G. Shao. 2017. 5-Aza-2ʹ-deoxycytidine, a DNA methylation inhibitor, induces cytotoxicity, cell cycle dynamics and alters expression of DNA methyltransferase 1 and 3A in mouse hippocampus-derived neuronal HT22 cells. Journal of Toxicology and Environmental Health, Part A 80:1222–29. doi:10.1080/15287394.2017.1367143.
   PubMed Web of Science ®Google Scholar
• Zhang, M., H. X. Zheng, Y. Y. Gao, B. Zheng, J. P. Liu, H. Wang, Z. J. Yang, and Z. Y. Zhao. 2017. The influence of Schisandrin B on a model of Alzheimer’s disease using β-amyloid protein Aβ1-42-mediated damage in SH-SY5Y neuronal cell line and underlying mechanisms. Journal of Toxicology and Environmental Health, Part A 80:1199–205. doi:10.1080/15287394.2017.1367133.
   PubMed Web of Science ®Google Scholar
• Zhang, X. D., T. Nguyen, W. D. Thomas, J. E. Sanders, and P. Hersey. 2000. Mechanisms of resistance of normal cells to TRAIL induced apoptosis vary between different cell types. FEBS Letters 482:193–99. doi:10.1016/S0014-5793(00)02042-1.
   PubMed Web of Science ®Google Scholar